A Phase II, Multi-center, Single Arm, Open Label Study to Assess Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 03 Jan 2017 Planned End Date changed from 1 Jan 2020 to 1 Mar 2020.
- 03 Jan 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Mar 2020.
- 03 Jan 2017 Planned initiation date changed from 1 Aug 2017 to 1 Oct 2017.